Kaplan-Meier estimates of overall survival (OS) in patients with advanced systemic mastocytosis depending on the karyotype and the mutation status in the SRSF2/ASXL1/RUNX1 gene panel (S/A/R). Pairwise significantly different OS probabilities were observed for the comparison good-risk karyotype + S/A/R^neg (n=27) vs. good-risk karyotype + S/A/R^pos (n=31) vs. poor-risk karyotype (n=9).